Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ramelteon sublingual adjunctive therapy study in bipolar I depression
2012-001357-10Phase 3Terminated
- Sponsor
- Takeda
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ramelteon in bipolar I disorder and bipolar disorder (BD) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in MADRS total score at Week 6. Started Oct 2012; status: terminated.
02
Drugs
ramelteon
03
Conditions
bipolar I disorderbipolar disorder (BD)
Beyond the preview
Go deeper on 2012-001357-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001357-10.